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Introduction: Cytology screening has been effective in reducing risks for cervical 
squamous cell carcinoma but less so for adenocarcinoma. We explored the associa-
tion of atypical glandular cells or absence of glandular cells in cytology, and subse-
quent histological diagnoses and cancer risk.
Material and methods: All women in Norway with atypical glandular cells of undeter-
mined significance (AGUS), adenocarcinoma in situ (ACIS) and normal/benign cells, 
but absence of endocervical or metaplastic cells (NC-NEC) in their first cytology dur-
ing 1992-2014 (NC-NEC; 2005-2014), recorded in the Cancer Registry of Norway, 
were included (n = 142 445). Histology diagnoses (stratified by age) within 1 and 
3 years after cytology were examined. The Nelson-Aalen cumulative hazard function 
for gynecological cancer risk was displayed.
Results: The majority of AGUS and particularly ACIS were followed with histology 
within 1 and 3 years. Cervical intraepithelial neoplasia (CIN) lesions were more com-
mon in women <35 than in women ≥35 years. Cervical adenocarcinoma followed 
13% of ACIS after 1 and 3 years. After ACIS and AGUS, cervical adenocarcinoma was 
the most frequent cancer subtype. Cumulative risks of cervical adenocarcinoma fol-
lowing ACIS, AGUS and NC-NEC were 3.5%, 0.9% and 0.05%, respectively, after 22, 
22 and 9 years of follow up.
Conclusions: There was a high-risk of glandular malignancies after AGUS and ACIS in 
cytology. If effective treatment of pre-cancer and early cancer is available, cytology 
screening provides some level of prevention of adenocarcinoma. Lack of glandular 
cells did not entail a higher cancer risk.
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1  | INTRODUC TION
Cervical cancer is the fourth most common cancer among women 
worldwide, with around 570 000 new cases and 310 000 deaths in 
2018.1 Well-organized cervical cancer screening programs have pro-
duced profound decreases in incidence and mortality of the disease.2,3 
In Norway, a decline in cervical cancer incidence and mortality was 
seen after the implementation of organized screening in 1995, but inci-
dence rates seem to have increased during recent years.3
The Norwegian Cervical Cancer Screening Program (NCCSP) 
invites all women aged 25-69 years to screening with cytological 
smears every 3 years.4 The screening coverage in the target age 
group is 69% within 3.5 years (2013-2016).3 Low-grade squamous 
cell cytological abnormalities are triaged with human papillomavi-
rus (HPV) testing and intensified screening, whereas high-grade 
cytological abnormalities warrant immediate referral to colpos-
copy and biopsy.5 Randomized implementation of HPV primary 
screening started in four Norwegian counties in 2015,6 and 
will be gradually implemented in the remaining counties during 
2019-2021.
In some settings, cervical screening using cytology has been re-
ported to reduce the risk of invasive adenocarcinomas,7,8 and lead to 
earlier detection of this type of cancer.9 However, cytology has been 
much more successful in reducing the risk of developing squamous 
cell carcinoma.2,8,10 Consequently, the relative contribution of these 
two main histological subtypes to the total cervical cancer burden 
has been changing over decades in countries with effective screen-
ing programs.11
The proportions of cytological smears that display dysplasia 
and/or abnormalities vary considerably between countries (0.98%-
15.5%).12-16 Histological diagnosis of adenocarcinoma in situ (ACIS) 
can follow either glandular or squamous cytological abnormalities. In 
American material, about 3%-4% of women with abnormal cytology 
have ACIS in histology.17,18
Of all cervical smears, 0.1%-2.1% are classified as atypical glan-
dular cells of undetermined significance (AGUS).17,19,20 A significant 
proportion of women with such smears have underlying cancer, or 
will develop cancer during follow up.20 Among women with AGUS 
in cytology in a US primary-care study, 19.5% had cancerous squa-
mous or glandular lesions of the cervix or endometrium and 11.5% 
had pre-cancerous squamous or glandular lesions.21 In a Swedish co-
hort study, women with atypical glandular cells (AGC), equivalent to 
AGUS, in cervical screening had a higher risk of incident cervical car-
cinoma, especially adenocarcinoma, than women with a high-grade 
squamous intraepithelial lesion.22 The cumulative incidence of inva-
sive cervical cancer was persistently elevated for up to 15.5 years 
following AGC in cytology.
Smears labelled as normal/benign cells, but with absence of endo-
cervical or metaplastic cells (NC-NEC) in our study show normal cells, 
but lack endocervical or metaplastic cells. As such, the condition of 
endocervical or metaplastic cells cannot be evaluated in these samples. 
NC-NEC smears are managed as normal smears in NCCSP.5 A Canadian 
review from 2011 suggested that the absence of endocervical cells in 
smears does not indicate a higher risk for underlying cervical abnor-
malities,23 but little is known in the Norwegian setting.
This study aimed to describe the association between atypical 
glandular changes in cervical cytology; AGUS, ACIS and NC-NEC, 
and subsequent diagnoses verified by histology. We also examined 
the risk of developing cervical cancer by histological subtype and 
other gynecological malignancies over time.
2  | MATERIAL AND METHODS
2.1 | Data sources
Data from the Cancer Registry of Norway (CRN), including NCCSP, 
were used.
The CRN was established in 1953 and covers the entire popula-
tion. The registry contains information on all new cancer cases and 
certain pre-cancerous lesions. Site, histological type and stage of 
disease at the time of diagnosis are reported, and clinical notifica-
tions, pathological notifications and death certificates are the main 
reporting sources. The coding and classification systems at CRN 
follow international standards. Reporting of cancer cases is com-
pulsory in Norway, and the data have been evaluated to be accurate 
and close to complete.24
The NCCSP is an integrated part of the Norwegian national 
healthcare system, and is managed by the CRN. The program 
receives mandatory reports from public and private pathology 
and microbiology laboratories, and keeps complete records of cy-
tology, histology and HPV test results. Individual screening data 
are recorded and organized into four sub-registries; the Cytology 
Register (since 1991), the Histology Register (since 2002), the 
HPV Test Register (since 2005) and the cervical intraepithe-
lial neoplasia (CIN) Register (since 1997).25 The CIN Register 
also includes follow-up and treatment data. The Bethesda and 
the SNOMED coding systems, with some local adaptions and 
changes over time, have been used for classification (cytology 
and histology).26
2.2 | Study population
This study included all women in Norway with AGC in their first 
registered cervical cytology (AGUS and ACIS) since 1992, and all 
women with NC-NEC in their first cervical cytology since 2005 
(when this category was adopted) (n = 142 445) (Figure 1). We 
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excluded women who had a diagnosis of invasive cervical cancer 
or other gynecological malignancies before their first cytology 
(n = 2017).
2.3 | Statistical analyses
Histology diagnoses recorded within 1 and 3 years after cervical 
cytology during 2002-2014 for AGUS and ACIS and during 2005-
2014 for NC-NEC, and stratified by age (<35 and ≥35 years), were 
descriptively displayed using contingency tables. No information 
on histology was available before 2002. Due to small numbers, 
no statistical tests examining differences between groups were 
performed.
The Nelson-Aalen cumulative hazard function for risk of gyne-
cological cancers, with 95% CIs, was calculated.27 We identified all 
gynecological cancers, cervical cancer (International Classification 
of Diseases 7th revision [ICD-7]; 171), uterine corpus cancer (ICD-7; 
172), ovarian cancer (ICD-7; 175.0) and vulvar/vaginal cancers 
(ICD-7; 176). The two main histological sub-groups of cervical can-
cer (squamous cell carcinoma and adenocarcinoma) were considered 
separately. Follow up started at 3 months after the cervical smear 
to exclude prevalent cancers detected at the index screen, and 
ended at diagnosis of a gynecological cancer, emigration, death or 
31 December 2013, whichever occurred first.
The data were analyzed using IBM SPSS Statistics 22 (IBM Corp., 
Armonk, NY, USA) and Stata/IC 14.0 (StataCorp., College Station, 
TX, USA).
2.4 | Ethical approval
The Regional Committee for Medical and Health Research Ethics of 
Western Norway approved the study (REK ref. number 2014/1918).
3  | RESULTS
3.1 | Characteristics of the study population
The median ages at ACIS, AGUS and NC-NEC were 43, 44 and 
45 years, respectively. Within 1 and 3 years of cytology, respec-
tively, 91% and 92% of ACIS, 76% and 78% of AGUS, and 2% and 
3% of NC-NEC smears were followed by a histological diagnosis 
(2002-2014).
3.2 | Association between cytological smears and 
histological diagnoses
Dysplastic lesions, premalignant lesions and cervical malignancies 
such as adenocarcinomas and squamous cell carcinomas were more 
frequent after ACIS cytology, and there were no major differences 
after 1 year (74.3%) and 3 years of cytology (75.4%). Following AGUS 
and ACIS cytology, 55.6% and 20.2% of the histological diagnoses 
within 3 years were normal or benign, respectively. CIN3 accounted 
for the majority of the CIN lesions following both AGUS and ACIS, 
whereas CIN1/2 were more frequent following AGUS cytology than 
ACIS after both 1 and 3 years. Overall, CIN1-3 accounted for 26.7% 
and 28.6% of the histological diagnoses within 1 and 3 years of 
AGUS, and 27.3% and 26.6% within 1 and 3 years of ACIS cytology 
(Tables 1 and 2). Following AGUS cytology, 38.7% and 41.7% of the 
histological diagnoses were dysplastic, premalignant and malignant 
(about 25% were CIN3, ACIS or more severe within 1 and 3 years). 
The majority of the histological diagnoses following NC-NEC within 
1 (81.1%) and 3 years (77.4%) were normal or benign. CIN1-3 ac-
counted for 12.0% and 15.9% of the histological diagnoses within 1 
and 3 years, respectively (Tables 1 and 2).
3.3 | Association between cytological smears and 
histological diagnoses, stratified by age
Following ACIS cytology, the proportion of CIN1 and CIN2 histol-
ogy was similar in women aged <35 and ≥35 years (Tables 3 and 4). 
ACIS was the most common histology diagnosis in both age groups. 
Malignant lesions had a higher proportion in women ≥35 than in 
women <35 years following ACIS cytology. There was a larger 
proportion of CIN lesions overall in women <35 than in women 
≥35 years following AGUS cytology. Histology diagnosis of invasive 
adenocarcinoma was more common in women ≥35 years, whereas 
the proportion of squamous cell carcinoma following AGUS cytology 
was similar in women <35 and ≥35 years (Tables 3 and 4). Normal 
F I G U R E  1   Selection of the study population; all women in 
Norway diagnosed with atypical glandular changes and normal/
benign cells, but absence of endocervical or metaplastic cells, 
in their first cervical cytology during 1992-2014. 1Normal/
benign cells, but absence of endocervical or metaplastic cells; 
recorded since 2005. 2Atypical glandular cells of undetermined 
significance. 3Adenocarcinoma in situ [Color figure can be viewed 
at wileyonlinelibrary.com]
144,462 women with cervical smears
during 1992-2014
Exclusions:
2017 women with a gynecological
malignancy prior to the cervical smear
142,445 women with cervical smears
during 1992-2014 
NC-NEC1 (n = 130 455)
AGUS2 (n = 10 019)
ACIS3 (n = 1971)
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and benign was the most common histology after NC-NEC in both 
women <35 years (over 50% within 1 and 3 years) and ≥35 years (over 
80% within 1 and 3 years) (Tables 3 and 4). There were few histologi-
cal diagnoses of ACIS following NC-NEC cytology within 3 years in 
women <35 (0.8%) and ≥35 (0.2%) years (Table 4). Malignant lesions 
(squamous cell carcinoma and adenocarcinoma) were rare in both 
age groups.
3.4 | Cumulative risk of gynecological cancer 
according to cervical cytology
A total of 121 023 women were followed from 3 months after the 
cervical smear (Table 5). For ACIS, AGUS and NC-NEC the mean 
follow-up times were 12.6, 10.3 and 4.6 years, respectively. Of the 
women with ACIS, AGUS and NC-NEC in cytology, 6.5%, 2.6% and 
0.3% developed gynecological cancer. For ACIS and AGUS, cervical 
cancer was the most common gynecological cancer and adenocar-
cinoma was the most frequent histological subtype. The cumulative 
risk of all gynecological cancers increased steeply in women with 
ACIS during the first 2 years, and continued to increase during fol-
low up (Figure 2). The cumulative risks were lower for AGUS. The 
cumulative risks of all gynecological cancers following ACIS, AGUS 
and NC-NEC were 8.1%, 5.5% and 0.9% after 22, 22 and 9 years of 
follow up, respectively. For cervical adenocarcinoma, the cumulative 
risks were 3.5%, 0.9% and 0.05%.
4  | DISCUSSION
In this nationwide population-based cohort study, we described the 
association between atypical glandular changes in cervical cytol-
ogy and subsequent diagnoses verified by histology. We also exam-
ined the risk of developing cervical cancer and other gynecological 
malignancies over time. Women <35 years old were more likely to 
have premalignant lesions (CIN1/2/3 and ACIS) after verified AGUS 
or ACIS cytology. There were no major differences 1 and 3 years 
after ACIS cytology, where 74.3% and 75.4% had developed dys-
plastic lesions, premalignant lesions and cervical malignancies. The 
figures after AGUS cytology were 38.7% and 41.7%, respectively. 
TA B L E  1   Distribution of histology diagnoses recorded within 
1 year of cervical cytology, Norway, 2002/05-2014
 Cytology
Histology NC-NECa AGUSb ACISc
 n % n % n %





112 5.3 92 2.3 11 1.7
Most likely 
malignant
3 0.1 60 1.5 4 0.6
CIN1 101 4.8 294 7.3 16 2.5
CIN2 45 2.1 169 4.2 18 2.8
CIN3 105 5.0 617 15.3 141 22.0
Irregular glandular 
epithelium
4 0.2 73 1.8 14 2.2




11 0.5 41 1.0 11 1.7
Adenocarcinoma 1 0.0 102 2.5 84 13.1
Unspecified or 
other
1 0.0 6 0.1 5 0.8
Metastasis 11 0.5 26 0.6 19 3.0
Total 2099 100 4045 100 640 100
Abbreviation: CIN, cervical intraepithelial neoplasia.
aNormal/benign cells, but absence of endocervical or metaplastic cells; 
recorded since 2005. 
bAtypical glandular cells of undetermined significance. 
cAdenocarcinoma in situ. 
TA B L E  2   Distribution of histology diagnoses recorded within 
3 years of cervical cytology, Norway, 2002/05-2014
 Cytology
Histology NC-NECa AGUSb ACISc
 n % n % n %





176 4.7 93 2.1 11 1.5
Most likely 
malignant
11 0.3 67 1.5 6 0.8
CIN1 198 5.3 349 7.7 19 2.6
CIN2 106 2.8 202 4.5 21 2.9
CIN3 291 7.8 742 16.4 154 21.2
Irregular glandular 
epithelium
6 0.2 84 1.9 18 2.4




23 0.6 51 1.1 12 1.6
Adenocarcinoma 5 0.1 113 2.5 94 12.9
Unspecified or 
other
3 0.1 7 0.2 6 0.8
Metastasis 16 0.4 31 0.7 29 4.0
Total 3751 100 4520 100 728 100
Abbreviation: CIN, cervical intraepithelial neoplasia.
aNormal/benign cells, but absence of endocervical or metaplastic cells; 
recorded since 2005. 
bAtypical glandular cells of undetermined significance. 
cAdenocarcinoma in situ. 
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After ACIS, 66.3% and 66.8% developed CIN3+ after 1 and 3 years, 
whereas the figures were 24.0% and 26.1% after AGUS. The high risk 
of high-grade lesions after AGUS justifies the immediate diagnostic 
verification and follow up of this lesion. Gynecological cancer most 
frequently followed ACIS cytology, and cervical adenocarcinoma 
was the most common histological subtype. Normal and benign was 
the most common histology after NC-NEC, and malignant lesions 
were rare.
More than half of the histological diagnoses following AGUS 
smears were normal or benign, and more common in women 
>35 years of age in our study. This is in line with a review where 11 
of 19 included studies reported a predominance of benign or normal 
histology following AGUS/AGC, but where normal and benign find-
ings varied from 20% to 80% in the different studies.20
Still, a significant proportion of women with AGUS have or will 
develop high-grade histological lesions and some may also develop 
gynecological cancer. In our study, about a quarter of the women 
with AGUS were diagnosed with high-grade histological lesions 
within 1 year. These might be considered underlying lesions de-
tected by cytology screening. A 2016 meta-analysis of 12 studies 
on high-risk HPV testing in the management of AGC, indicated that 
20% of women with AGC developed CIN2+/ACIS+ when followed 
up by the screening program in the respective countries.28 In total, 
about 5% of women with AGC cytology in that analysis had ACIS+ 
histology. Cervical malignancies (squamous cell carcinoma, adeno-
carcinoma and adenosquamous carcinoma) were detected in 3.6%.
Marques et al20 did a systematic review of 19 articles that ad-
dressed the correlation of AGUS/AGC in cytology and benign, prema-
lignant and malignant lesions. Premalignant squamous lesions were 
predominant in 6 of the articles whereas cervical adenocarcinoma and 
endometrial adenocarcinoma had proportion ranges of 0%-18%29,30 
and 0%-29%,29,31 respectively. Another relatively recent Australian 
study (2015) found that 11.8% of women with atypical endocervical 
cells (AEC) cytology had or developed an ACIS or CIN2/3 histology di-
agnosis within 5 years, and 0.7% and 3.8% of women were diagnosed 
with cervical and endometrial carcinomas, respectively.32
Previous research has found that women aged 24-35 years 
with AEC more likely have high-grade cervical dysplasia than older 
women, especially during the first 3-4 years following the AEC 
smear.32 Our findings also indicated a higher proportion of high-
grade cervical dysplasia among women <35 years of age within 1 
and 3 years after AGUS cytology. Because sexual intercourse with 
new partners remains a risk factor for HPV infection and the rates of 
acquiring new partners decline with age, these findings may be cor-
related to the natural course of HPV infections in younger women. 
According to Schiffman et al,33 the majority of newly acquired HPV 
infections become undetectable within 1-2 years. However, HPV 
infections persistently detected beyond 12 months increase the 
TA B L E  3   Distribution of histology diagnoses recorded within 1 year of cervical cytology, Norway, 2002/05-2014, in women <35 and 
≥35 years of age
 Cytology
 NC-NECa AGUSb ACISc
 <35 y ≥35 y <35 y ≥35 y <35 y ≥35 y
Histology n % n % n % n % n % n %
Total 336 100.0 1763 100.0 848 100.0 3197 100.0 165 100.0 475 100.0
Normal/benign 198 58.9 1504 85.3 329 38.8 2033 63.6 23 13.9 111 23.4
Insufficient or unsatisfactory 
material for diagnosis
4 1.2 108 6.1 10 1.2 82 2.6 1 0.6 10 2.1
Most likely malignant 0 0 3 0.2 5 0.6 55 1.7 0 0 4 0.8
CIN1 52 15.5 49 2.8 69 8.1 225 7.0 6 3.6 10 2.1
CIN2 18 5.4 27 1.5 64 7.5 105 3.3 4 2.4 14 2.9
CIN3 59 17.6 46 2.6 235 27.7 382 11.9 41 24.8 100 21.1
Irregular glandular epithelium 0 0.0 4 0.2 21 2.5 52 1.6 6 3.6 8 1.7
ACIS 1 0.3 2 0.1 90 10.6 113 3.5 65 39.4 118 24.8
Cervical cancer
Squamous cell carcinoma 4 1.2 7 0.4 9 1.1 32 1.0 1 0.6 10 2.1
Adenocarcinoma 0 0 1 0.1 16 1.9 86 2.7 17 10.3 67 14.1
Unspecified or other 0 0 1 0.1 0 0 6 0.2 1 0.6 4 0.8
Metastasis 0 0 11 0.6 0 0 26 0.8 0 0 19 4.0
Abbreviation: CIN, cervical intraepithelial neoplasia.
aNormal/benign cells, but absence of endocervical or metaplastic cells; recorded since 2005. 
bAtypical glandular cells of undetermined significance. 
cAdenocarcinoma in situ. 
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risk of carcinogenic progression to cervical pre-cancer or cancer if 
untreated. 
In our study, 2.6% of women with AGUS developed gynecolog-
ical cancer and 1.3% developed cervical cancer after a mean follow 
up of 10.3 years. A Swedish cohort study by Wang et al22 assessed 
the short-term and long-term risks of cervical cancer after AGC 
cytology with a mean follow up of 10 years, and found a prevalence 
of cervical cancer of 1.4%.
Cervical cancer and uterine corpus cancer were the most com-
mon gynecological cancers following AGUS cytology in our study. 
Adenocarcinoma constituted more than half of the cervical cancer 
cases following AGUS cytology, whereas about 40% were squamous 
cell carcinoma. Wang et al22 found that the most prevalent cervical 
cancers were diagnosed within 6 months after AGC, and the highest 
incidence and prevalence of cervical cancer were found in women 
aged 30-39 years. Adenocarcinoma was the main histological sub-
type of cervical cancer (73.2%), whereas squamous cell carcinoma 
accounted for 22.1%. This would imply an even higher specificity 
of AGC for carcinomas of the glandular subtype than found in our 
material for AGUS cytology. Together, these findings indicate that a 
considerable cancer risk is associated with AGUS cytology.
Munro et al32 found that 4.8% of women with AEC had invasive 
malignancies. Endometrial cancer was most frequent, especially in 
women >45 years of age. Geier et al18 found only 0.2% endometrial 
adenocarcinomas (1 case within 1 year of follow up), whereas the 
TA B L E  4   Distribution of histology diagnoses recorded within 3 years of cervical cytology, Norway, 2002/05-2014, in women <35 and 
≥35 years of age
 Cytology
 NC-NECa AGUSb ACISc
 <35 y ≥35 y <35 y ≥35 y <35 y ≥35 y
Histology n % n % n % n % n % n %
Total 726 100.0 3025 100.0 985 100.0 3535 100.0 196 100.0 532 100.0
Normal/benign 373 51.4 2530 83.6 357 36.2 2156 61.0 26 13.3 121 22.7
Insufficient or unsatisfactory 
material for diagnosis
11 1.5 165 5.5 10 1.0 83 2.3 1 0.5 10 1.9
Most likely malignant 1 0.1 10 0.3 5 0.5 62 1.8 0 0 6 1.1
CIN1 101 13.9 97 3.2 80 8.1 269 7.6 7 3.6 12 2.3
CIN2 53 7.3 53 1.8 70 7.1 132 3.7 5 2.6 16 3.0
CIN3 174 24.0 117 3.9 285 28.9 457 12.9 44 22.4 110 20.7
Irregular glandular epithelium 1 0.1 5 0.2 21 2.5 59 1.7 8 4.1 10 1.9
ACIS 6 0.8 7 0.2 121 12.3 147 4.2 82 41.8 138 25.9
Cervical cancer
Squamous cell carcinoma 5 0.7 18 0.6 14 1.4 37 1.0 1 0.5 11 2.1
Adenocarcinoma 1 0.1 4 0.1 18 1.8 95 2.7 21 10.7 73 13.7
Unspecified or other 0 0 3 0.1 0 0 7 0.2 1 0.5 5 0.9
Metastasis 0 0 16 0.5 0 0 31 0.9 0 0 20 3.8
Abbreviation: CIN, cervical intraepithelial neoplasia.
aNormal/benign cells, but absence of endocervical or metaplastic cells; recorded since 2005. 
bAtypical glandular cells of undetermined significance. 
cAdenocarcinoma in situ. 
TA B L E  5   Gynecological malignancies following cervical 
cytology, 1992-2013
 Cytology
Characteristics NC-NECa AGUSb ACISc
Mean follow up (y)d 4.6 10.3 12.6
Number and proportion (%) of malignancies following cytology
Cervical cancere (ICD-7; 171) 55 (0.0) 116 (1.3) 65 (4.2)
Adenocarcinoma 12 (0.0) 61 (0.7) 45 (2.9)
Squamous cell carcinoma 41 (0.0) 46 (0.5) 14 (0.9)
Other 2 (0.0) 8 (0.1) 6 (0.4)
Uterine corpus cancer (ICD-7; 172) 200 (0.2) 64 (0.7) 15 (1.0)
Ovarian cancer (ICD-7; 175.0) 97 (0.1) 31 (0.4) 18 (1.2)
Vulvar/vaginal cancers (ICD-7; 
176)
25 (0.0) 6 (0.1) 1 (0.1)
All gynecological cancers 386 (0.3) 221 (2.6) 101 (6.5)
Abbreviation: ICD-7, International Statistical Classification of Diseases 
and Related Health Problems, 7th revision.
aNormal/benign cells, but absence of endocervical or metaplastic cells; 
recorded since 2005. 
bAtypical glandular cells of undetermined significance. 
cAdenocarcinoma in situ. 
dStart of follow up 3 months after the cervical smear; end of follow up 
31 December 2013; number. of women 121 023. 
eOne case of cervical cancer was not histologically verified. 
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study by Scheiden et al31 resulted in 29% endometrial adenocarcino-
mas. Zhao et al30 also showed a relatively high proportion of endo-
metrial cancer (27%). In our study, uterine corpus cancer constituted 
29% of all gynecological cancers following AGUS cytology.
Studies have shown that only a minority of women (estimates 
vary from 28% to 44%) who developed cervical adenocarcinoma 
had a preceding AGC or AGUS smear. This might indicate that other 
measures besides better management of AGC or AGUS, such as HPV 
screening, have the potential to improve the prevention of glandular 
diseases of the cervix.34
In NCCSP, smears labeled NC-NEC are followed as normal 
smears with a recommended screening interval of 3 years. In our 
study, 3% of women with NC-NEC in cytology were followed with 
histology within 3 years, and almost 80% of these were normal or 
benign. Altogether 55, 116 and 65 women with NC-NEC, AGUS and 
ACIS in cytology, respectively, developed cervical cancer over time. 
Assuming that the women in the different cytology categories had a 
cervical cancer risk similar to that of the general female population, 
the expected numbers would have been 95, 17 and 4, respectively. 
Consequently, there seems to be no increased risk of cervical cancer 
in women with normal smears lacking endocervical or metaplastic 
cells. Also, other longitudinal studies have shown no increased risk 
of high-grade lesions or cancer in women with smears without sam-
pling from the transformation zone.23,35
Our study was based on complete records of the results from 
all cytology (NC-NEC, AGUS and ACIS) and histology specimens 
from the CRN/NCCSP. Among the strengths of our study were the 
population-based design, including all women with AGUS, ACIS and 
NC-NEC in their first cervical cytology, and the follow up of women 
over time.
Despite the assessment of complete records from national 
registries, some of the outcomes were very rare, and provided 
small numbers. The number of cervical cancer cases, especially 
following NC-NEC, was low. Also, ACIS was a relatively rare cy-
tological result, especially in women <35 years. Besides, histology 
diagnoses following AGUS and ACIS were recorded since 2002, 
but for NC-NEC only since 2005. Altogether, this limited our use 
of statistical tests and complicated the interpretation of results. 
Therefore, the majority of the results presented in our study were 
descriptive.
Histology was not available for all women, and in particular 
only for 3% of those with NC-NEC cytology, potentially leading to 
F I G U R E  2   Cumulative risk of gynecological cancer according to cervical cytology, 1992/2005-2013. ACIS, adenocarcinoma in situ; 
AGUS, atypical glandular cells of undetermined significance; NC-NEC, normal/benign cells, but absence of endocervical or metaplastic cells; 
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verification bias. The indication for biopsy in this group of women is 
not known but may relate to other risk factors such as genital symp-
toms or clinical findings, and the rate of normal histology in the total 
population of NC-NEC women is therefore likely to be higher.
Our study did not include information on hysterectomy and/or 
oophorectomy. The rates of hysterectomy are, however, lower in 
Norway (1.2 per 1000) than other western countries, such as the 
USA (5.4 per 1000) or Italy (3.7 per 1000).36
Follow up started 3 months after the cervical smear when we eval-
uated the cumulative risk of gynecological cancer to leave out most 
prevalent cancers diagnosed immediately after the index screen from 
the analyses. The slope of the cumulative hazard curves show that 
diagnostic events are frequent in the beginning of follow up, so the 
absolute levels of observed risk are somewhat sensitive to the start 
of follow up. Starting follow up at 6 months instead of 3 months as a 
sensitivity analysis, the pattern of risk was similar, but with an up to 
20% decrease in the absolute level (in cervical cancer after ACIS). Some 
prevalent cancers are still likely to be included in the analysis.
5  | CONCLUSION
In this nationwide population-based cohort study, 78% of AGUS 
and 92% of ACIS smears were followed by histology within 3 years. 
Of these, 42% of the histological findings following AGUS, and 
75% following ACIS were dysplastic, premalignant or malignant. 
Approximately 27% and 71% of the histological findings were CIN3, 
ACIS or more severe (including metastases) following AGUS and ACIS 
cytology, respectively. Only 3% of the NC-NEC smears were followed 
with histology within 3 years, and of these, 77% were normal or be-
nign. During follow up, 6.5% and 2.6% of women with ACIS and AGUS 
smears developed gynecological cancer, respectively, and cervical 
adenocarcinoma was the most common subtype. This indicates that 
a considerable risk is associated with ACIS and AGUS cytology, and 
such findings warrant careful gynecological evaluation. According 
to this study, closer follow up of women with NC-NEC may not be 
required.
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